Elevidys Gene Therapy Shows Positive Results in Duchenne Muscular Dystrophy Trial

Sarepta Therapeutics announced positive topline results from the EMBARK phase 3 trial of its gene therapy Elevidys for Duchenne muscular dystrophy on June 18, 2024. The trial evaluated Elevidys in 125 ambulatory boys aged 4 to 7 years with Duchenne muscular dystrophy. Elevidys is designed to deliver a functional micro-dystrophin gene to muscle cells.

The trial met its primary endpoint, with Elevidys-treated patients showing a statistically significant improvement in North Star Ambulatory Assessment scores compared to placebo at week 52. The North Star Ambulatory Assessment measures motor function in Duchenne muscular dystrophy patients.

Secondary endpoints, including time to rise from the floor and 10-meter walk/run test, also favored the treatment group, though some did not reach statistical significance.

Muscular Dystrophy and Prior Treatments Duchenne

muscular dystrophy is a genetic disorder caused by mutations in the dystrophin gene, leading to progressive muscle weakness and loss of ambulation, typically by the early teens.

It affects approximately 1 in 3,500 to 5,000 male births worldwide. Without treatment, life expectancy is around 20 to 30 years due to respiratory and cardiac complications. The field has seen developments in exon-skipping therapies, which aim to restore partial dystrophin production by skipping mutated gene segments.

Sarepta's earlier exon-skipping drug eteplirsen received accelerated FDA approval in 2016 based on increased dystrophin levels, despite mixed clinical outcomes. Subsequent drugs like golodirsen and casimersen followed similar paths, but larger trials have shown limited functional benefits, raising questions about efficacy.

The EMBARK trial was a randomized, double-blind, placebo-controlled study conducted at multiple sites in the United States and Europe.